deltatrials
Completed PHASE4 INTERVENTIONAL 2-arm NCT02946892

Effect of Carvedilol on Exercise Performance in Fontan Patients

Sponsor: American Heart Association

Updated 12 times since 2017 Last updated: Jan 11, 2021 Started: Nov 30, 2016 Primary completion: Dec 31, 2019 Completion: Jan 31, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Fontan and Single Ventricle, this trial is completed. The trial is conducted by American Heart Association and has accumulated 12 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Study Description(click to expand)

Carvedilol is a well studied heart failure medication in adult heart failure that has been shown to improve outcomes. However, it has not been studied in patients who have had a Fontan heart operation. Study participants will receive either placebo or carvedilol for 12 weeks, at the end of the 12 weeks participants will perform an exercise test. Then study participants will receive treatment with placebo or carvedilol for 12 weeks (opposite of what participants go the first 12 weeks) and will again perform an exercise test.

Carvedilol is a well studied heart failure medication in adult heart failure that has been shown to improve outcomes. However, it has not been studied in patients who have had a Fontan heart operation. Study participants will receive either placebo or carvedilol for 12 weeks, at the end of the 12 weeks participants will perform an exercise test. Then study participants will receive treatment with placebo or carvedilol for 12 weeks (opposite of what participants go the first 12 weeks) and will again perform an exercise test.

Status Flow

~Jan 2017 – ~Jul 2017 · 6 months · monthly snapshotNot Yet Recruiting~Jul 2017 – ~Jun 2018 · 11 months · monthly snapshotRecruiting~Jun 2018 – ~Mar 2019 · 9 months · monthly snapshotRecruiting~Mar 2019 – ~Mar 2020 · 12 months · monthly snapshotRecruiting~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshotCompleted~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshotCompleted~Feb 2021 – ~Dec 2022 · 22 months · monthly snapshotCompleted~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotCompleted~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 19 months · monthly snapshotCompleted~Jan 2026 – present · 3 months · monthly snapshotCompleted

Change History

12 versions recorded
  1. Jan 2026 — Present [monthly]

    Completed PHASE4

  2. Sep 2024 — Present [monthly]

    Completed PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  4. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE4

  5. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE4

Show 7 earlier versions
  1. Feb 2021 — Dec 2022 [monthly]

    Completed PHASE4

  2. Jan 2021 — Feb 2021 [monthly]

    Completed PHASE4

  3. Mar 2020 — Jan 2021 [monthly]

    Completed PHASE4

    Status: RecruitingCompleted

  4. Mar 2019 — Mar 2020 [monthly]

    Recruiting PHASE4

  5. Jun 2018 — Mar 2019 [monthly]

    Recruiting PHASE4

  6. Jul 2017 — Jun 2018 [monthly]

    Recruiting PHASE4

    Status: Not Yet RecruitingRecruiting

  7. Jan 2017 — Jul 2017 [monthly]

    Not Yet Recruiting PHASE4

    First recorded

Nov 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • American Heart Association
  • University of Texas Southwestern Medical Center
Data source: University of Texas Southwestern Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations